International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 001-008
THE VALUE OF TUMOUR MARKERS IN DIFFERENTIAL DIAGNOSIS OF MALIGNANT AND BENIGN EFFUSIONS
ÖZLEM ER1, BERNA ÖKSÜZOĞLU1, ALİ ÖZ1, HULKİ GENÇ1, SAADET AKDUR1, MUSTAFA ESEN1
Ankara Numune Eğitim ve Araştırma Hastanesi 5. Dahiliye Kliniği, ANKARA
Keywords: tumour markers, malignant effusion, benign effusion
To determine importance of tumor markers in differential diagnosis of malignant and benign effusion, we studied AFP, CEA, CA19-9, CA15-3 in serum and effusion simultaneously in 81 patients with pleural or peritoneal effusion. In malignant effusion group, 29 male, 22 female totally 51 patients were included, mean age was 53.3 years. In benign effusion group, 17 male, 13 female totally 30 patients were included, mean age was 54 years. Effusion CEA, CA19-9, CA15-3 levels were significantly higher in malignant effusion group than benign effusion group. Malignant effusion group was subgrouped according to etiology and comparison was made among groups. Serum and effusion AFP level in HCC group, serum CEA in GIS tumor, effusion CEA level in lung cancer, breast cancer, ovary cancer and GIS tumor group, serum and effusion CA19-9 level in tumor of unknown primary and GIS tumor group, serum CA15-3 in breast cancer and tumor of unknown primary, effusion CA15-3 level especially in breast cancer group and also in lung cancer, tumor of unknown primary, ovary cancer, GIS tumor group were significantly higher than benign effusion group. Differential diagnosis of malignant and benign effusion is difficult, studying effusion tumor marker level may be useful in differentiation.
ÖZLEM ER1, BERNA ÖKSÜZOĞLU1, ALİ ÖZ1, HULKİ GENÇ1, SAADET AKDUR1, MUSTAFA ESEN1
Ankara Numune Eğitim ve Araştırma Hastanesi 5. Dahiliye Kliniği, ANKARA
Keywords: tumour markers, malignant effusion, benign effusion
To determine importance of tumor markers in differential diagnosis of malignant and benign effusion, we studied AFP, CEA, CA19-9, CA15-3 in serum and effusion simultaneously in 81 patients with pleural or peritoneal effusion. In malignant effusion group, 29 male, 22 female totally 51 patients were included, mean age was 53.3 years. In benign effusion group, 17 male, 13 female totally 30 patients were included, mean age was 54 years. Effusion CEA, CA19-9, CA15-3 levels were significantly higher in malignant effusion group than benign effusion group. Malignant effusion group was subgrouped according to etiology and comparison was made among groups. Serum and effusion AFP level in HCC group, serum CEA in GIS tumor, effusion CEA level in lung cancer, breast cancer, ovary cancer and GIS tumor group, serum and effusion CA19-9 level in tumor of unknown primary and GIS tumor group, serum CA15-3 in breast cancer and tumor of unknown primary, effusion CA15-3 level especially in breast cancer group and also in lung cancer, tumor of unknown primary, ovary cancer, GIS tumor group were significantly higher than benign effusion group. Differential diagnosis of malignant and benign effusion is difficult, studying effusion tumor marker level may be useful in differentiation.